Heterogeneity of CD40 Expression in Different Types of High-Risk Endometrial Cancer Affects Discordant Prognostic Outcomes

BACKGROUND: The role of immune checkpoint inhibitors in endometrial cancer is limited. At present, the anti-programmed cell death protein 1 (anti-PD-1) antibody is only used in patients with recurrence or metastasis. CD40 is an important immune checkpoint, which is expressed in tumor cells and immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Na, Sun, Bowen, Cheng, Yuan, Wang, Jianliu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317534/
https://www.ncbi.nlm.nih.gov/pubmed/37404251
http://dx.doi.org/10.2147/TCRM.S416220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317534/
https://www.ncbi.nlm.nih.gov/pubmed/37404251
http://dx.doi.org/10.2147/TCRM.S416220

Ejemplares similares